Tacrines as Therapeutic Agents for Alzheimer's Disease. V. Recent Developments

被引：20

作者：

Bautista-Aguilera, Oscar M. ^{[1
]}

Ismaili, Lhassane ^{[2
]}

Iriepa, Isabel ^{[1
,3
]}

Diez-Iriepa, Daniel ^{[1
]}

Chabchoub, Fakher ^{[4
]}

Marco-Contelles, Jose ^{[5
]}

Perez, Marta ^{[6
]}

机构：

[1] Univ Alcala, Dept Quim Organ & Quim Inorgan, Ctra Madrid Barcelona,Km 33,6, Madrid 28871, Spain

[2] Univ Bourgogne Franche Comte, Lab Chim Organ & Therapeut, Neurosci Integrat & Clin EA 481, UFR Sante, 19 Rue Ambroise Pare, F-25000 Besancon, France

[3] Alcala Univ, Inst Chem Res Andres M del Rio, Madrid 28805, Spain

[4] Univ Sfax, Lab Chim Appl Heterocycles Corps Gras & Polymeres, Fac Sci Sfax, BP 802, Sfax 3000, Tunisia

[5] CSIC, Lab Med Chem IQOG, Juan de la Cierva 3, Madrid 28006, Spain

[6] Univ Basque Country, Publ Hlth Dept, Fac Med & Nursing, Leioa, Spain

来源：

CHEMICAL RECORD | 2021年 / 21卷 / 01期

关键词：

Alzheimer' s disease; Cholinesterase inhibition; Friedlä nder reaction; Hepatotoxicity; Tacrine derivatives; BIOLOGICAL ASSESSMENT; DIRECTED LIGANDS; SENILE DEMENTIA; ACETYLCHOLINESTERASE; INHIBITORS; DRUGS; FLUORESCEIN; MELATONIN; HYBRIDS; DESIGN;

D O I：

10.1002/tcr.202000107

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Herein we have reviewed our recent developments for the identification of new tacrine analogues for Alzheimer's disease (AD) therapy. Tacrine, the first cholinesterase inhibitor approved for AD treatment, did not stop the progression of AD, producing only some cognitive improvements, but exhibited secondary effects mainly due to its hepatotoxicity. Thus, the drug was withdrawn from the clinics administration. Since then, many publications have described non-hepatotoxic tacrines, and in addition, important efforts have been made to design multitarget tacrines by combining their cholinesterase inhibition profile with the modulation of other biological targets involved in AD.

引用

页码：162 / 174

页数：13

共 50 条

[21] Tau Protein Aggregation in Alzheimer's Disease: Recent Advances in the Development of Novel Therapeutic Agents
Monteiro, Kadja L. C.
Alcantara, Marcone G. dos S.
de Aquino, Thiago M.
da Silva-Junior, Edeildo F.
[J]. CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (15) : 1682 - 1692
[22] Epigenetic Inhibitors as Alzheimer's Disease Therapeutic Agents
Yamashita, Yasunobu
Itoh, Yukihiro
Takada, Yuri
Suzuki, Takayoshi
[J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2024, 72 (07) : 630 - 637
[23] Therapeutic Treatment of AICAR for Microglial Inflammation in Alzheimer's Disease.
Ayasolla, K. R.
Rahimipour, S.
Malhotra, A.
Singhal, P. C.
[J]. JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2012, 7 : S62 - S62
[24] Alzheimer's disease.
Gagnon, M
Sweet, L
[J]. CANADIAN JOURNAL ON AGING-REVUE CANADIENNE DU VIEILLISSEMENT, 2000, 19 (02): : 282 - 284
[25] Recent advances in the therapeutic development for Alzheimer's disease
Gao, Xinyi
Zhang, Juan
Liu, Qiang
[J]. CHINESE SCIENCE BULLETIN-CHINESE, 2024, 69 (17): : 2351 - 2359
[26] Alzheimer's Disease: A Review of Recent Developments and the Role of Imaging
Ismail, Hicham
Wang, Lily
[J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[27] Fluid biomarkers for Alzheimer's disease: standardization and recent developments
Zetterberg, Henrik
Visser, Pieter Jelle
[J]. BIOMARKERS IN MEDICINE, 2012, 6 (04) : 363 - 364
[28] Recent developments in chotinesterases inhibitors for Alzheimer's disease treatment
Musial, Anna
Bajda, Marek
Malawska, Barbara
[J]. CURRENT MEDICINAL CHEMISTRY, 2007, 14 (25) : 2654 - 2679
[29] Genetic and biochemical markers for Alzheimer's disease: recent developments
Mulder, C
Scheltens, P
Visser, JJ
van Kamp, GJ
Schutgens, RBH
[J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2000, 37 : 593 - 607
[30] Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines
de los Rios, Cristobal
Marco-Contelles, Jose
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 166 : 381 - 389

← 1 2 3 4 5 →